Clinical trial
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00017121 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00017121 |
|---|---|
| Title | Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung |
| Official title | Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Metastatic Cancer |
| Intervention type | Biological |
| Interventions | sargramostim |
| Enrollment | 40 |
| Start date | May 1, 2002 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: